Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

17.77 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Novocure Reports First Quarter 2025 Financial Results
From Novocure
Via Business Wire
Earnings Scheduled For April 24, 2025
Via Benzinga
NovoCure's Earnings: A Preview
Via Benzinga
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
Via The Motley Fool
Earnings Scheduled For February 27, 2025
Via Benzinga
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Why NovoCure Stock Was Withering on Wednesday
Via The Motley Fool
Novocure to Report First Quarter 2025 Financial Results
From Novocure
Via Business Wire
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
From Novocure
Via Business Wire
Why NovoCure Stock Was Winning Big This Week
Via The Motley Fool
Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds
The company is soon to seek regulatory approval in the U.S. and abroad. 
Via Investor's Business Daily
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025
NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion. 
Via Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
From Novocure
Via Business Wire
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks. 
Via Benzinga
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. 
Via Benzinga
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Zai Lab
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.